🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "huge turning point" in the battle against superbug strains of the infection, according to researchers.

An International Public Health Issue

The sexually transmitted infection are on the rise globally, with estimates suggesting over 82 million infections annually. Especially elevated rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which spans from China and Mongolia to New Zealand. Within England, cases have reached a historical peak, while figures across Europe in 2023 were significantly elevated compared to those in 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, increasing antimicrobial resistance and the extremely scarce available drugs at this time.”

Medical experts are particularly alarmed about the rise in drug-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Therapies Secure Approval

Zoliflodacin, also known as a brand name, was approved by the US Food and Drug Administration in December for treating gonorrhoea. This STI can lead to major issues, including the inability to conceive. Experts hope that targeted use of this new drug will help delay the emergence of superbugs.

Gepotidacin, developed by the drugmaker GSK, was also approved in concurrent days. This treatment, which is employed against urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.

“This authorization marks a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing medical innovation.”

Testing Results and Global Access

According to data released by a major medical journal, the new drug eradicated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the current standard treatment, which combines an injection and a pill. The trial included nearly 1,000 volunteers from multiple nations including the United States, Thailand, South Africa, and European nations.

As part of the agreement of its development partnership, GARDP has the authority to license and sell the drug in numerous regions with limited resources.

Medical professionals treating patients have shared positive views. Having a one-pill regimen like this is hailed as a "revolutionary step" for public health efforts. This is viewed as crucial to reduce the burden of the infection for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.